Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
Phuong Khanh Morrow, Board Member of Reagan-Udall Foundation for the FDA, Senior Vice President and Head of Oncology Therapeutic Area Unit (OTAU) at Takeda, Board Member of Lantheus, shared a post on LinkedIn:
“Patients living with PV often have limited treatment options to help them manage this chronic and difficult blood cancer. This shines a light on the pressing need for additional treatment options.
As an oncologist, an FDA approval is never just a milestone – it’s a moment where science meets real possibility for patients!
This approval represents an important step forward for the PV community.
Progress like this underscores why continued scientific innovation matters and why we remain focused on advancing options that can make a meaningful difference for patients!”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 03:54Jennifer Trowbridge: How Mutant Blood Stem Cells Use Inflammation to Drive Their Own Expansion
-
Oct 19, 2026, 03:39Wyenona Hicks: Catching Up With Old Friends and New Colleagues at AABB 2026
-
Oct 19, 2026, 03:33Developing a Non-Invasive Treatment for Life-Threatening PE – University of Michigan College of Engineering
-
Oct 19, 2026, 03:28Jim Hoffman: How NETs Contribute to Gallstone Formation and Growth
-
Oct 19, 2026, 03:28Nicolas Hubacz: The Organized Chaos of Mitochondria
-
Oct 19, 2026, 03:02Neda Horvacki: Using ROTEM to Refine Transfusion Decisions in Acute Trauma
-
Oct 19, 2026, 02:45Diego Escarraman Martinez: MATTERs Study – When a Cohort Gave Us Major Clues about TXA in Trauma
-
Oct 19, 2026, 02:35Brian O Mahony: Promoting Physical Activity and Sport in Haemophilia Care
-
Oct 19, 2026, 02:35Malusi Mtetwa: Tranexamic Acid – What Does the Evidence Tell Us?